Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)

This “allocated fund in clinical research” was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years.

News & Events

Posted on

The ISREC Foundation is pleased to support the next AGORA workshop dedicated to multimodal imaging.

Read more
Posted on

Congratulations to Prof. Johanna Joyce and her teams for the publication in the distinguished Cell Reports Medicine journal. The study analyzed brain…

Read more
Posted on

Congratulations to Prof. Denis Migliorini, M.D., holder of the ISREC Foundation’s Brain Tumor Immunology Chair, and his team: along with Prof. Andrea…

Read more
Posted on

FLASH radiotherapy, an innovative and interdisciplinary technology, is perfectly in line with our goal of supporting translational cancer research. …

Read more